Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Ponesimod in Relapsing Multiple Sclerosis
NCT03232073Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2017
- Primary completion
- Jan 2024
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of ponesimod in multiple sclerosis (MS), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2017; status: completed.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03232073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232073.